Background/Objectives: Prostate cancer is the most prevalent malignancy in men and remains a leading cause of cancer-related mortality worldwide. Conventional imaging modalities exhibit limited sensitivity, particularly in the context of disease recurrence and advanced disease.Methods: A narrative review was conducted of studies published between 2015 and 2025, identified through PubMed, Embase, and Cochrane. Eligible publications addressed advanced imaging techniques, PSMA-targeted diagnostics and therapies, radiogenomics, liquid biopsy approaches, and artificial intelligence applications and personalized medicine. Preclinical studies, single case reports, and conference abstracts without full text were excluded.Results: PSMA PET/CT outperforms conventional imaging for detection, and restaging, influencing clinical management across disease stages. Lutetium-177–PSMA-617 has become the standard radioligand therapy for metastatic castration-resistant prostate cancer, whereas alpha-emitting agents remain under clinical investigation. Radiogenomics and liquid biopsy assays (ctDNA, CTCs, AR-V7) provide complementary molecular insights. Artificial intelligence enhances imaging interpretations, standardization, and reproducibility, while multimodal data integration supports individualized risk stratification. Integrative models combining imaging, genomic, and liquid biopsy data pave the way toward precision oncology and personalized therapeutic decision-making.Conclusions: Advances in imaging and theragnostics are reshaping prostate cancer management, bridging the gap between molecular biology and clinical practice to enable precision oncology.
背景/目的：前列腺癌是男性中最常见的恶性肿瘤，也是全球癌症相关死亡的主要原因之一。传统影像学方法在检测灵敏度方面存在局限，尤其在疾病复发和晚期阶段表现不足。 方法：本研究对2015年至2025年间通过PubMed、Embase和Cochrane数据库检索到的文献进行了叙述性综述。纳入文献涵盖先进影像技术、PSMA靶向诊断与治疗、放射基因组学、液体活检方法、人工智能应用及个体化医疗。排除标准包括临床前研究、单病例报告及无全文的会议摘要。 结果：PSMA PET/CT在疾病检测和再分期方面优于传统影像学，对各阶段临床决策产生重要影响。镥-177–PSMA-617已成为转移性去势抵抗性前列腺癌的标准放射性配体疗法，而α粒子放射治疗药物仍处于临床研究阶段。放射基因组学与液体活检技术（ctDNA、CTCs、AR-V7）提供了互补的分子生物学信息。人工智能提升了影像解读的标准化与可重复性，多模态数据整合支持个体化风险分层。结合影像学、基因组学和液体活检数据的整合模型为精准肿瘤学和个体化治疗决策开辟了新路径。 结论：影像学与诊疗一体化技术的进步正在重塑前列腺癌的临床管理，弥合分子生物学与临床实践之间的鸿沟，推动精准肿瘤学的发展。
Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI-Driven Biomarkers
肿瘤(癌症)患者之家